At the 2023 SNO Annual Conference, Imvax displayed novel findings advocating for its principal project, IGV-001, targeting recently identified Glioblastoma.

On 11 Dec 2023, the updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2) in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) will be reported in 2023 ASH.

HOOKIPA Pharma Inc. has officially disclosed that the FDA has given the clearance for its IND application for HB-500, This is a new arenaviral therapeutic vaccine designed for HIV treatment.

JAK2 inhibitors: Revolutionizing treatments for hematological disorders with a promising future.

Sandoz announces the launch of its citrate-free high concentration Hyrimoz® (adalimumab) in Europe, with availability starting today in various countries.

On 11 Dec 2023, The clinical data about Axicabtagene Ciloleucel from pivotal ZUMA-7 study will be updated in 2023 ASH.

European Commission gives the green light to Ascendis Pharma's YORVIPATH® (palopegteriparatide) for managing chronic Hypoparathyroidism in adults.

The KRAS mutation, as a significant driving factor for non-small cell lung cancer, has long been a challenging type of mutation. However, the recent development and clinical application of various KRAS inhibitors have brought us new hope.

ProMIS Neurosciences initiates Phase 1a clinical trial, injecting the first participants with PMN310, a potential Alzheimer’s Disease treatment.

On 11 Dec 2023, the final phase III APPLY-PNH trial data after a 24-wk extension period in which all pts received iptacopan monotherapy will be reported in 2023 ASH.

Immix Biopharma confirms IND application for CAR-T NXC-201 has been sanctioned by FDA, allowing treatment dosage for U.S. patients.

IL-23 inhibitors are a class of drugs that target the cytokine IL-23, playing a crucial role in treating inflammation and autoimmune diseases.